



Department of Defense US Army Medical Research and Materiel Command



Fiscal Year 2002 Chronic Myelogenous Leukemia Program

Table of Contents

Introduction

Fiscal Year 2002 Chronic Myelogenous Leukemia Funded Awards

Investigator-Initiated Award

Fiscal Year 2002 Chronic Myelogenous Leukemia Program Participants

Peer Reviewers

Integration Panel Reviewers (IP)

Ad Hoc Programmatic Reviewers

Glossary of Terms

Introduction

The US Army Medical Research and Materiel Command is pleased to present the award list of funded projects for the fiscal year 2002 (FY02) Chronic Myelogenous Leukemia Research Program. Award negotiations were completed by June 16, 2003. The awards listed in this document were selected by a competitive two-tier review process. Funding decisions were based on scientific excellence evaluated in the first tier of review, followed by programmatic relevance judged in the second tier. These projects represent a diverse portfolio of scientific research directed toward the program's overall goal of improving (1) the understanding of the basic science of chronic myelogenous leukemia, (2) the diagnosis of chronic myelogenous leukemia, (3) the treatment of chronic myelogenous leukemia, and (4) the quality of life for individuals living with chronic myelogenous leukemia and their families.

Congressional direction for FY02 specified \$5 million for chronic myelogenous leukemia research. Following the receipt of funds, a programmatic strategy was developed, proposals were solicited and evaluated, award recommendations were made, and contract negotiations were completed. The Investigator-Initiated Award was developed in response to the FY02 programmatic strategy. The intent of this award mechanism is to sponsor basic and clinically oriented research in the field of chronic myelogenous leukemia. The program encouraged the submission of innovative, high-risk studies that explore novel ideas and contain little or no preliminary data. The program initially funded 6 of 48 Investigator-Initiated Award submissions. An additional four proposals were funded with FY03 congressionally directed funding.

As the funded scientists embark on these projects, the Department of Defense and the US Army gratefully acknowledge the participation of their scientific advisors, people living with chronic myelogenous leukemia, and the chronic myelogenous leukemia advocacy community. The expertise, vision, and diversity of perspectives of all individuals who contributed to this program were vital to developing a sound investment strategy on behalf of all persons living with chronic myelogenous leukemia. It is with great anticipation and excitement that we await the outcomes of this research.

Investigator-Initiated Awards

Log Number	PI Last Name	PI First Name	Institution	Proposal Title	Final Budget
CM020006	Zhang	Dong-Er	The Scripps Research Institute	Protein ISG15 Modification in the Development and the Treatment of Chronic Myeloid Leukemia	\$750,000
CM020008	Platanias	Leonidas	Northwestern University	Map Kinase Pathways as Therapeutic Targets in Chronic Myelogenous Leukemia	\$750,000
CM020016	Ilaria, Jr.	Robert	University of Texas Southwestern Medical Center	Novel Targeted Approaches for de Novo and STI571 (Imatinib)-Resistant Bcr/Abl-Induced Leukemia	\$732,888
CM020021	Jordan	Craig	University of Rochester	Targeted Ablation of CML Stem Cells	\$748,915
CM020024	Grant	Steven	Virginia Commonwealth University	Histone Deacetylase Inhibitor-Based Strategies for Imatinib-Resistant CML	\$748,632
CM020027	Issa	Jean-Pierre	University of Texas M.D. Anderson Cancer Center	Epigenetic Silencing and Resistance to Imatinib Mesylate in CML	\$750,000
CM020031	Katsanis	Emmanuel	The University of Arizona	Chaperone Rich Cell Lysate (CRCL) Vaccine for Chronic Myelogenous Leukemia	\$264,515
CM020044	Perrotti	Danilo	Ohio State University	Effect of BCR/ABL Oncoprotein on mRNA Translation: Possible Mechanisms Responsible for CML Disease Progression	\$750,000
CM020049	Shlomchik	Warren	Yale University School of Medicine	Mechanisms of Graft-vs-Leukemia Against a Novel Murine Model of Blast Crisis Chronic Myelogenous Leukemia	\$749,991
CM020058	Shannon	Kevin	University of California, San Francisco	Role of the SHP2 Phosphatase in Myeloid Growth Control and Chronic Myeloid Leukemia	\$185,421

FY02 Chronic Myelogenous Leukemia Research Program
Peer Reviewers

Peer Reviewer	Degree	Institution/Affiliation
Barry, Michael	Ph.D.	Baylor College of Medicine
Bhatia, Ravi	M.D.	City of Hope National Medical Center
Bouhassira, Eric	Ph.D.	Albert Einstein College of Medicine
Cranmer, David		The Leukemia & Lymphoma Society
Gabrilove, Janice	M.D.	The Mount Sinai Medical Center
George, Donna	Ph.D.	University of Pennsylvania
Gillies, Robert	Ph.D.	University of Arizona
Goins, William	Ph.D.	University of Pittsburgh School of Medicine
Harris, Kimberly		The Leukemia & Lymphoma Society
Helman, Sandy	Ph.D.	Scientific Review Administrator
Hunger, Stephen	M.D.	University of Florida College of Medicine
Jhanwar, Suresh	Ph.D.	Memorial Sloan Kettering Cancer Center
Kurzrock, Razelle	M.D.	University of Texas, MD Anderson Cancer Center
Mauro, Michael	M.D.	Oregon Health and Science University
Melnick, Ari	M.D.	Albert Einstein College of Medicine
Molldrem, Jeffrey	M.D.	University of Texas M.D. Anderson Cancer Center
Ness, Scott	Ph.D.	University of New Mexico Health Science Center
Ren, Ruibao	M.D., Ph.D	Brandeis University
Rowe, John		The Leukemia & Lymphoma Society
Sawyers, Charles	M.D.	University of California Los Angeles
Van Etten, Richard	M.D., Ph.D.	The Center for Blood Research

**Fiscal Year 2002 Chronic Myelogenous Leukemia Research Program
Integration Panel (IP) Members**

IP Members	Degree	Institution/Affiliation
Gewirtz, Alan	M.D.	University of Pennsylvania School of Medicine
Kinniburgh, Alan	Ph.D.	The Leukemia & Lymphoma Society
Lee, Stephanie	M.D., MPH	Dana-Farber Cancer Institute
McCullough, Rose	Ph.D.	US Agency for International Development
Roberts, Thomas	Ph.D.	University of Chicago
Schwartz, Anna	Ph.D.	University of Washington
Talpaz, Moshe	M.D.	University of Texas, M.D. Anderson Cancer Center

**Fiscal Year 2002 Chronic Myelogenous Leukemia Research Program
Ad Hoc Programmatic Reviewer**

Ad Hoc Reviewer	Degree	Institution/Affiliation
Broxmeyer, Hal	Ph.D.	Indiana University School of Medicine

Glossary of Terms

Investigator-Initiated Research Award: The intent of Investigator-Initiated Research Award is to sponsor basic and clinically oriented research in the field of chronic myelogenous leukemia. These grants are intended to fund independent investigators across a broad spectrum of disciplines. Investigators are encouraged to submit proposals with novel ideas or approaches in promising areas that may not be developed enough to compete for traditional funding. The Fiscal Year 2002 Chronic Myelogenous Leukemia Research Program encourages investigators to submit proposals that address the molecular and genetic changes underlying chronic myelogenous leukemia disease progression, the identification of therapeutic targets in drug-resistant cells, and the understanding of immune system involvement in the control of chronic myelogenous leukemia.